REVIEW
533  Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
Cholankeril G, Patel R, Khurana S, Satapathy SK

ORIGINAL ARTICLE
544  Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients

Observational Study
551  Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

CASE REPORT
562  18-Fluoro-deoxyglucose uptake in inflammatory hepatic adenoma: A case report
ABOUT COVER

Editorial Board Member of World Journal of Hepatology, Sanjaya K Satapathy, MBBS, MD, DM, FACC, FASGE, Associate Professor of Surgery Transplant Hepatologist, Division of Gastroenterology and Hepatology, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, Memphis, TN 38104, United States

AIM AND SCOPE

World Journal of Hepatology (World J Hepatol, WJH, online ISSN 1948-5182, DOI: 10.4254), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJH covers topics concerning liver biology/pathology, cirrhosis and its complications, liver fibrosis, liver failure, portal hypertension, hepatitis B and C and inflammatory disorders, steatohepatitis and metabolic liver disease, hepatocellular carcinoma, biliary tract disease, autoimmune disease, cholestatic and biliary disease, transplantation, genetics, epidemiology, microbiology, molecular and cell biology, nutrition, geriatric and pediatric hepatology, diagnosis and screening, endoscopy, imaging, and advanced technology. Priority publication will be given to articles concerning diagnosis and treatment of hepatology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to WJH. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Hepatology is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, and Scopus.

FLYLEAF

Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Dan Li
Proofing Editor-in-Chief: Lian-Sheng Ma

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
36 Issues/Year (8th, 18th, and 28th of each month)

EDITORS-IN-CHIEF
Clara Balsamo, PhD, Professor, Department of Biomedicine, Institute of Molecular Biology and Pathology, Rome 00161, Italy

Wan-Long Chuang, MD, PhD, Doctor, Professor, Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

EDITORIAL BOARD MEMBERS
All editorial board members resources online at http://www.wjgnet.com/1948-5182/editorialboard.htm

EDITONAL OFFICE
WJH
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLISHER
Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLICATION DATE
April 18, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
http://www.wjgnet.com/bpg disseurinfo/204

ONLINE SUBMISSION
http://www.wjgnet.com
18-Fluoro-deoxyglucose uptake in inflammatory hepatic adenoma: A case report

Willy Liu, Jean Delwaide, Noella Bletard, Philippe Delvenne, Paul Meunier, Roland Hustinx, Olivier Detry

Abstract
Positron emission tomography computed tomography (PET-CT) using 18-Fluoro-deoxyglucose ($^{18}$FDG) is an imaging modality that reflects cellular glucose metabolism. Most cancers show an uptake of $^{18}$FDG and benign tumors do not usually behave in such a way. The authors report herein the case of a 38-year-old female patient with a past medical history of cervical intraepithelial neoplasia and pheochromocytoma, in whom a liver lesion had been detected with PET-CT. The tumor was laparoscopically resected and the diagnosis of inflammatory hepatic adenoma was confirmed. This is the first description of an inflammatory hepatic adenoma with an $^{18}$FDG uptake.

Key words: Liver surgery; Liver tumor; Liver cancer; Benign tumor; Laparoscopy; Prognosis

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
liver cancer. In this paper, the authors report the first description of an inflammatory hepatic adenoma with $^{18}$FDG uptake.


INTRODUCTION

Hepatocellular adenomas (HCAs) are rare benign hepatic tumors that are more frequent in women and have been associated with oral contraceptive use[1]. The risk of malignant transformation of HCAs is small but non-negligible[2]. The commonest complication of HCAs is bleeding, an occurrence which has been linked to multiple factors such as the size of the adenoma, pregnancy, visualization of lesional arteries, left lateral lobe location and exophytic growth. Due to these risks, recent guidelines have recommended the resection of adenomas that present: A diameter larger than 50 mm, signs of hepatocarcinoma or focal dysplasia, activated β-catenin mutation, high level of serum alphafetoprotein, hepatocellular adenomas developing in male gender or hepatocellular adenomas developing in a glycogen storage disease[3]. The resection is regularly performed as laparoscopic hepatectomy[4]. Positron emission tomography computed tomography (PET-CT) using 18-Fluoro-deoxyglucose ($^{18}$FDG) is an imaging modality that is based on an enhancement of glucose consumption, a distinguishing feature of most cancers that is in part related to the over-expression of GLUT-1 glucose transporters and increased hexokinese activity. The use of PET-CT in primary or secondary liver cancer is increasing[5-8]. As HCAs are benign lesions, they are not assumed to be $^{18}$FDG-avid, except in some rare cases. To the best of their knowledge, the authors described herein the first report of $^{18}$FDG uptake by an inflammatory HCA (I-HCA), and reviewed the literature for other reports of $^{18}$FDG uptake in other types of liver adenoma.

CASE REPORT

A 38-year-old female patient had a past medical history of cervical intraepithelial neoplasia treated with cervical conisation, and a pheochromocytoma that was laparoscopically resected in 2011. She was followed up with yearly magnetic resonance imaging (MRI) that demonstrated a segment 1 liver tumor whose size increased of 20 mm in two years. This 50-mm lesion bore the MRI features of HCA, showing a heterogeneous signal intensity on T-2 weighted images and low-signal intensity on T-1 weighted images. The lesion was slowly and gradually enhanced after injection of gadolinium without significant wash-out on portal phase (Figure 1). In addition, a left renal cyst was noticed, described as type 3 according to the Bosniak classification. An $^{18}$FDG PET-CT was performed to further confirm the nature of the hepatic lesion and exclude extrhepatic metastases. The liver lesion appeared hypermetabolic with a standardized uptake value (SUVmax) of 9.3. A percutaneous biopsy was performed and immunohistology allowed the diagnosis of I-HCA. Blood carcinoembryonic antigen, carbohydrate antigen 19.9 and alphafetoprotein were negative. A discussion in a multi-disciplinary oncological team meeting led to the decision of the resection of the hepatic lesion. A laparoscopic resection of hepatic segment 1 was performed, extended to segments 2 and 3 due to the location of the tumor at the junction between the inferior vena cava, the left and middle hepatic veins and the left branch of the portal vein. During the same anesthesia, the left kidney mass was resected through a lombotomy, following the preferences of the urologist. The surgical specimen was analyzed and showed slightly clarified hepatocytes scattered throughout the lesion, fibrous tracts with vascular structures within, probably arteries with thick walls (Figure 3). Some inflammatory components surrounded these arteries and there was no significant sinusoidal dilatation. At immunohistochemistry, serum amyloid A was negative and anti-C reactive protein antibodies showed a significant expression of the inflammatory protein around blood vessels, confirming I-HCA (Figure 4). Inflammatory cells were CD3 positive (Figure 5). The immediate post-operative state was excellent, without significant pain and fast oral feeding. The length of hospital stay was 5 d. The patient was seen again one month later for an evaluation visit and no particular problems were observed.

DISCUSSION

This report describes the occurrence of a 50-mm I-HCA that was highly avid for $^{18}$FDG at PET-CT. The exact nature of this I-HCA was confirmed by surgical resection. To the best of the authors’ knowledge, this is the first report of $^{18}$FDG uptake by an I-HCA. HCAs are classified into four types, according to their genetic and histologic features (Table 1): HNF1α inactivated HCA (H-HCA), β-catenin mutated HCA (β-HCA), I-HCA and unclassified HCA[7,8]. The actual risk of malignancy of all HCAs is evaluated at 4.2%[3-5]. The β-HCA subtype is associated with the highest risk of malignant transformation and must be resected (Table 1). After literature review, the authors found 22 other HCA cases with $^{18}$FDG uptake in PET-CT[19-19] (Table 2), and none of them was the inflammatory type. Eighteen of them have a description of the histological findings with steatosis. Twelve reported a final diagnosis, which was either HNF1α or hepatic adenomatosis.

The uptake of $^{18}$FDG results from the increased metabolism of the cell. The intracellular FDG accumulation is proportional to the amount of glucose utilization[20] and most cancers do have increased cellular activity.
The differential diagnosis of benign $^{18}$FDG avid hepatic lesions might include focal steatosis, infectious, parasitic or inflammatory processes (e.g., hepatic abscess, cryptococcal infection, hepatic tuberculosis) and hepatic adenoma. Focal fatty infiltration has been reported to be PET-avid. In fact, as a response to fat accumulation, a subacute inflammatory hepatic reaction with infiltration of activated Kupffer cells may occur, resulting in a higher SUVmax than adjacent normal liver parenchyma. As said above, five cases of hepatic adenoma showed fatty changes but none of them were of the inflammatory type. Only one had a few inflammatory infiltrates. Maybe the fatty change itself was sufficient enough to induce a PET-avid response, without obvious inflammatory infiltrate in histological examination. It is also possible, as suggested by Nakashima et al., that the high expression of glucose transporters might be responsible for the increased uptake. Indeed, one study demonstrated that in H-HCA the
**Table 1  Classification of hepatocellular adenomas**

<table>
<thead>
<tr>
<th>HCA subtype</th>
<th>Abbreviation</th>
<th>Proportion</th>
<th>Markers</th>
<th>Malignant transformation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HNF1α inactivated</td>
<td>H-HCA</td>
<td>35%-40%</td>
<td>LFABP</td>
<td>Rare</td>
</tr>
<tr>
<td>β-catenin activated</td>
<td>β-HCA</td>
<td>10%</td>
<td>β-catenin/‘GS’ activated</td>
<td>Yes</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>I-HCA</td>
<td>50%</td>
<td>CRIP</td>
<td>No</td>
</tr>
<tr>
<td>Unclassified</td>
<td>U-HCA</td>
<td>5%</td>
<td>None</td>
<td>No</td>
</tr>
</tbody>
</table>

HCA: Hepatocellular adenoma.

**Table 2  Cases of 18-fluoro-deoxyglucose-avid hepatocellular adenomas reported in literature**

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Gender</th>
<th>Age (yr)</th>
<th>Size (mm)</th>
<th>SUVmax</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>[7]</td>
<td>Female</td>
<td>41</td>
<td>10</td>
<td>NA</td>
<td>HCA</td>
</tr>
<tr>
<td>[8]</td>
<td>Female</td>
<td>37</td>
<td>33</td>
<td>5</td>
<td>H-HCA</td>
</tr>
<tr>
<td>[9]</td>
<td>NA</td>
<td>44</td>
<td>30</td>
<td>6.2</td>
<td>HCA</td>
</tr>
<tr>
<td>[10]</td>
<td>Female</td>
<td>52</td>
<td>NA</td>
<td>4.09-9.8</td>
<td>Hepatic adrenomatosis</td>
</tr>
<tr>
<td>[12]</td>
<td>Male</td>
<td>69</td>
<td>40</td>
<td>10.4</td>
<td>H-HCA</td>
</tr>
<tr>
<td>[13]</td>
<td>4 cases</td>
<td>NA</td>
<td>73 ± 15</td>
<td>6 ± 0.5</td>
<td>HCA</td>
</tr>
<tr>
<td>[14]</td>
<td>Female</td>
<td>34</td>
<td>20-30</td>
<td>3.9</td>
<td>HCA</td>
</tr>
<tr>
<td>[15]</td>
<td>Male</td>
<td>73</td>
<td>25</td>
<td>11.9</td>
<td>Fatty liver</td>
</tr>
<tr>
<td>[16]</td>
<td>Female</td>
<td>44</td>
<td>23</td>
<td>7.9</td>
<td>H-HCA</td>
</tr>
<tr>
<td>[17]</td>
<td>9 cases</td>
<td>49 ± 16</td>
<td>27 ± 15</td>
<td>8.2 ± 4.3</td>
<td>H-HCA</td>
</tr>
<tr>
<td>This case</td>
<td>Female</td>
<td>38</td>
<td>50</td>
<td>9.3</td>
<td>I-HCA</td>
</tr>
</tbody>
</table>

HCA: Hepatocellular adenoma; 18FDG: 18-fluoro-deoxyglucose; H-HCA: HNF1α inactivated HCA; I-HCA: Inflammatory HCA; NA: Not available.

**Clinical diagnosis**
This tumor was asymptomatic and described at follow-up imaging after surgical resection of a pheochromocytoma.

**Differential diagnosis**
Adenoma, hepatocellular carcinoma, other primary or metastatic hepatic tumors.

**Laboratory diagnosis**
Blood tumor markers, and particularly alphafoetoprotein, were negative.

**Imaging diagnosis**
Magnetic resonance imaging was compatible with hepatocellular adenoma, but the lesion was 18-fluoro-deoxyglucose (18FDG) avid at positron emission tomography computed tomography (PET-CT).

**Pathological diagnosis**
Percutaneous biopsy and surgical specimen confirmed inflammatory hepatocellular adenoma (I-HCA).

**Treatment**
Laparoscopic liver R0 resection.

**Related reports**
To the authors’ knowledge, this case is the first report of a PET-CT FDG-avid I-HCA.

**Term explanation**
Hepatocellular adenomas are benign liver lesions whose imaging diagnosis could be uncertain.

**Experiences and lessons**
PET-CT positivity is not necessary linked to cancerous degeneration in liver adenomas.

Liu W et al. 18FDG and hepatic adenoma

LFABP gene ablation significantly increased the in-vitro expression of GLUT-2 but not that of GLUT-1[24]. Another study demonstrated that HNF1α-inactivated HCAs activate glycolysis due to a strong up-regulation of glucokinase[25]. These two components are features of most cancers (rise of GLUT-1 and hexokinase activity) with features of H-HCA (rise of GLUT-2 and glucokinase). However, due to the few reports published in literature, no conclusion can be made on the risk of cancer development in HCA with uptake of 18FDG. Prospective and large series are needed to confirm the role of PET-CT in HCA evaluation and prognosis.

**COMMENTS**

**Case characteristics**
A 5-cm liver tumor was diagnosed in a 38-year-old woman.

**Figure 5** Immunohistochemistry with anti-CD3 antibodies, positive in the inflammatory cells (arrow).
REFERENCES


